AzTrials
AzTrials

DementiaMARQUE2NCT02216396

A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes

An observational study of Dementia and Agitation, run by University College, London at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

One third of the population, aged over 65, live and will die with dementia. Half of people with dementia experience symptoms of agitation every month. Symptoms of agitation include restlessness, pacing, shouting and verbal or physical aggression. Read more about this study

Who is it for?
Any age
Conditions the study is for
Dementia, Agitation
How many people
1,734 participants
Where
1 siteUnited Kingdom
Study dates
Apr 2014to Dec 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: We will recruit care homes from across England. Our sampling frame will encompass all care homes types where people with dementia reside to ensure external validity and generalisability. We will recruit homes to ensure a representation of each provider type (voluntary, state and private) care provision (nursing, residential) and of urban/suburban and rural locations. There are around 18,000 English care homes and 80% of residents have dementia (Alzheimer's Society). We will include all people with dementia diagnosed or screening positive for possible dementia on the Noticeable Problems checklist, all care home staff who provide care for this population and family carers who are in regular contact.

Who may be able to join

  • We will seek care home managers' agreement for their care home's inclusion. We will note refusal, in order to consider external validity and use its predictors in a sensitivity analysis. In included homes, we will identify through the home care staff which people cared for have dementia using a carer proxy measure, the Noticeable Problems Checklist (Levin 1989) if they do not have a known dementia diagnosis. We will do this rather than screening residents using a cognitive measure, as it will not cause distress and is independent of culture and education. We will invite all people with dementia to participate.
  • We will also interview the consenting primary family carer of each resident included, if they see their relative at least monthly, and all consenting care team members, who provide hands-on care.

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Care homes across England

    London

Other trials in United Kingdom

About this study

Official title: MARQUE (Managing Agitation and Quality of Life) Stream 2: A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes

One third of the population, aged over 65, live and will die with dementia. Half of people with dementia experience symptoms of agitation every month. Symptoms of agitation include restlessness, pacing, shouting and verbal or physical aggression. Many people with agitation are admitted to care homes as families find they cannot care for them at home. Within the care home, staff also often find managing people with agitation difficult and they react in a wide range of ways. Agitated behaviour takes up staff time and emotional and physical energy but they do not always know how to respond. This study is one of the streams in an integrated programme to help tackle agitation in a variety of settings from domestic environments to end of life.

Our primary hypothesis is that for people with dementia living in care homes, paid carer use of dysfunctional coping strategies predicts lower quality of life in residents with dementia and that this is more so at higher levels of agitation.

We will recruit 60-80 care homes (residential or nursing homes). We will identify all residents with dementia, and the care home manager will approach them and their family carers. After obtaining informed consent, or advice from personal or nominated consultees for those lacking capacity, we will ask people with dementia who can answer questions about their quality of life using the DEMQOL. We will also ask staff and their family carers for those who have them, to rate the quality of life of the person with dementia using the DEMQOLproxy. We will ask care home staff other questions about residents with dementia, including about agitation, using the Cohen-Mansfield Agitation Inventory (CMAI), and the care they receive. Staff will also answer questions about the ways they cope with caring stresses, using the COPE. We will measure quality of life and agitation 5 times over 16 months. We will use our results to test our theory that agitation is an important factor determining residents quality of life, and that the ways staff cope with stress affect the impact agitation has on quality of life.

Read the detailed description

Research questions What is the relationship between paid carer coping, and agitation and quality of life in people with dementia living in care homes? What are the economic implications? What carer, resident and environmental characteristics predict better quality of life in this group, and should therefore be incorporated into our draft care home intervention before it is evaluated? Do agitation, quality of life and quality of care predict death? Primary hypothesis For people with dementia living in care homes, paid carer use of dysfunctional coping strategies predicts lower quality of life in residents with dementia and that this is more so at higher levels of agitation.

Methods Setting and sampling We will recruit care homes from across England. Our sampling frame will encompass all care homes types where people with dementia reside to ensure external validity and generalisability. We will recruit homes to ensure a representation of each provider type (voluntary, state and private) care provision (nursing, residential) and of urban/suburban and rural locations. We already carry out research with: Jewish Care, Dementia UK, Camden Adult Social Care, Springdene Care Homes group, BUPA Care Homes, Care UK and Abbey Care. We will also work with DeNDRoN ENRICH project (CC has been involved in North Thames pilot) and our project care home partners (Jewish Care, BUPA and Barchester) to recruit care homes. We have discussed with DeNDRoN ENRICH; the network has 389 research-ready care homes and is growing rapidly; our target is achievable by targeting larger homes including our collaborators; BUPA, Jewish Care and Barchester. There are around 18,000 English care homes and 80% of residents have dementia (Alzheimer's Society).

Procedures We will seek care home managers' agreement for their care home's inclusion. We will note refusal, in order to consider external validity and use its predictors in a sensitivity analysis. In included homes, we will identify through the home care staff which people cared for have dementia using a carer proxy measure, the Noticeable Problems Checklist (Levin 1989) if they do not have a known dementia diagnosis. We will do this rather than screening residents using a cognitive measure, as it will not cause distress and is independent of culture and education. We will invite all people with dementia to participate. Some will be able to give informed consent to take part, but the majority are unlikely to have capacity to do so. We will follow the Mental Capacity Act (2005) provisions when deciding whether to include people with dementia who do not have capacity, and in appointing professional consultees for those without a personal consultee as we have in previous studies(Jones et al. 2012). We will also interview the consenting primary family carer of each resident included, if they see their relative at least monthly, and all consenting care team members, who provide hands-on care. This is to understand the coping strategies used by all who care for them and the impact on residents. We will ask the paid carer working most closely with each resident with dementia to complete proxy measures. For each home we will record care home characteristics, including number of residents (in total and with dementia), staffing: resident ratios, turnover and details of regular home activities. All assessments will take place at the care home in a private room, for paid carers and residents; family carers may choose to be interviewed in the care home, in their own home or at UCL.

Measures Clinical research assistants will conduct interviews at baseline, 4, 8, 12 \& 16 months.

Analysis We will test our hypothesis that paid care teams using more dysfunctional coping strategies, is associated with people with dementia having a worse subsequent quality of life (measured using paid carer DEMQOL) and that is more so when their agitation levels are higher. We will take into account the influence of agitation and other predefined carer and resident environmental characteristics (e.g. specialist dementia home; nursing staff; dementia severity; resident sex and age). Hierarchical multiple regression models will be used to allow for the repeated measurements of quality of life over time and clustering by carer team. Interaction terms will be included in the models to consider differential effects of baseline agitation levels. We will conduct a cost-consequences analysis, reporting by different coping strategies the mean per patient resource use and costs, agitation and quality adjusted life years (QALYs) as measured by the DEMQoL. The net monetary benefit, calculated as mean per patient costs and QALYs multiplied by the amount a decision maker is willing to pay for a QALY. Analysis will also be reported by coping strategy. Descriptive statistics of mean per patient costs and resource use by agitation will also be included and will follow a predefined Statistical Analysis Plan (SAP). We will obtain date and cause of death from the ONS mortality data set; the Health and Social Care Information Centre will obtain this data for us by matching NHS number and date of birth against this database.

Sample size calculation In our START study the correlation between dysfunctional coping and quality of life was -0.31. To detect this magnitude of correlation with 90% power \& 5% significance requires 105 people with dementia(Machin et al. 2009). Adjustments to allow for clustering by care team (estimated average team size: 40 people with dementia; Intra cluster correlation (ICC: 0.075)(Fossey et al. 2006), impact of confounding (Variance Inflation Factor = 2) [8] \& an expected average 2.5 repeated measurements/person (based on 30% drop out/year) and correlation between repeated quality of life measurements of 0.75 (from START data) results in a total required sample size of 700. To investigate the interaction between coping strategy and high and low agitation groups will inflate sample size to 2800. This sample size will be reduced if cluster size is less than 40 people with dementia; to 1734 people with dementia based on 87 clusters with 20 people with dementia per cluster, or to 2000 people with dementia based on 80 clusters with 25 per cluster, or to 2537 people with dementia based on 72 clusters with 35 per cluster. Although not powered to show outcome we will investigate the responses of family carers and people with dementia in sensitivity analyses.

Conditions
Dementia, Agitation
Keywords
dementia, care home, agitation, coping
Medical subject headings
Dementia, Psychomotor Agitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DEMQOL and DEMQOL proxy

    quality of life of the person with dementia

    Measured: Up to 16 months

Secondary outcomes (6)
  1. Brief COPE (Coping Orientations to Problems Experienced)

    a multidimensional coping inventory that has been widely used to assess the different ways in which people respond to stress, including in nurses (Burgess et al. 2010). It is a self-report questionnaire with fourteen subscales describing different coping strategies, (with two items per scale) (Carver 1997b). We will ask care workers to score each strategy from 1 (not doing it at all) to 4 (doing it a lot). We used three subscales of the COPE for which adequate psychometric properties in dementia carers are reported (Cooper et al. 2008): problem-focussed (active coping, instrumental support and planning), emotion-focussed (acceptance, emotional support, humour, positive reframing and religion) and dysfunctional coping (behavioural disengagement, denial, self distraction, self-blame, substance use and venting).

    Measured: baseline

  2. Maslach burnout inventory

    one of the most commonly used measures of burnout in care home staff, and has adequate psychometric properties (Pitfield et al. 2011).

    Measured: baseline

  3. revised Modified Conflict Tactics Scale for professional carers

    a measure of possibly abusive behaviour staff may use to cope with the stresses of caring and problem behaviours which we have developed and piloted in care home staff in a previous study and have found to be acceptable. The professional carers will complete this questionnaire anonymously and results will not be linked to the rest of the study. We will record whether or not they have completed it in the research records. Staff will complete it in private and post it into a sealed box. We have used this system in the SILQ study successfully. We will record which care home the person completing the form worked in. While we will not be able to identify individual participants, we will notify the care home manager about any concerning abuse happening in the home, specifically if a staff member reports hitting or shaking a resident.

    Measured: baseline

  4. Cohen-Mansfield Agitation Inventory

    most commonly used measure of agitation in people with dementia (Cohen-Mansfield and Billig 1986).

    Measured: 0,4,8,12,16 months

  5. Neuropsychiatric Inventory

    measure of neuropsychiatric symptoms

    Measured: 0,4,8,12,16 months

  6. Client service receipt interview

    measure of resource use

    Measured: 0,4,8,12,16 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2014 (estimated)
  2. Study startApr 2014
  3. Primary completionAug 2016 (estimated)
  4. Study completionDec 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,734 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02216396
Sponsor's protocol ID
143438
Acronym
MARQUE2
Status last verified
May 2015
First submitted
4 Aug 2014
Last updated
4 Dec 2015
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Dementia and Agitation, run by University College, London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DEMQOL and DEMQOL proxy (time frame: Up to 16 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in